scout

Joyce A. O’Shaughnessy

Articles by Joyce A. O’Shaughnessy

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

ByAarti Chawla,Komal Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Joyce A. O’Shaughnessy,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Guiseppe Curigliano,Antonio Llombart-Cussac,Elgene Lim, MBBS, FRACP, PhD,María de la Luz García Tinoco,Joohyuk Sohn,Andre Mattar,Qingyuan Zhang,Chiun-Sheng Huang,Chih-Chiang Hung,Jorge Luis Martinez Rodriguez,Manuel Ruiz Borrego

46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

ByMatthew P. Goetz, MD,Masakazu Toi,Jens Huober, MD,Joohyuk Sohn,Oliver Trédan,In Hae Park,Mario Campone,Shin-Cheh Chen,Luis Manuel Manso,Shani Paluch-Shimon,Orit C. Freedman,Joyce A. O’Shaughnessy,Xavier Pivot,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Antonio Llombart,Valérie André,Abhijoy Saha,Gertjan van Hal,Ashwin Shahir,Hiroji Iwata,Stephen R.D. Johnston

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

ByElgene Lim, MBBS, FRACP, PhD,Adam M. Brufsky, MD, PhD,Hope S. Rugo, MD,Charles L. Vogel, MD, FACP,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Hannah M. Linden, MD

Latest Updated Articles